
Kelly Chibale leads a respected drug-discovery lab in South Africa that focuses on finding new medicines using creative chemistry and patient persistence. The emerging success in targeting KRAS mutations underscores the value of that kind of innovative chemistry and persistent lab work, and reinforces the global need for teams that can translate early discoveries into experimental treatments for urgent diseases.
Click a connection line between nodes to view confidence and evidence.